[{"id":"688b0cd4-fc6d-4c69-8add-f04838298a5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05491226","created_at":"2022-08-08T12:59:06.885Z","updated_at":"2025-02-25T13:41:10.335Z","phase":"Phase 2","brief_title":"Reinvigorating TNBC Response to Immunotherapy with Combination Myeloid Inhibition and Radiation","source_id_and_acronym":"NCT05491226","lead_sponsor":"Stephen Shiao","biomarkers":" HER-2 • PD-L1","pipe":"","alterations":" ","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Niktimvo (axatilimab-csfr)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 11/17/2023","start_date":" 11/17/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"6d0b40ae-0057-41ed-9ea5-d6965f8e7aa0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238027","created_at":"2021-01-18T16:00:03.519Z","updated_at":"2024-07-02T16:35:03.052Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors","source_id_and_acronym":"NCT03238027","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" PD-1 • IFNG • IL6 • TNFA • PD-L2 • IL2 • IL10 • CSF1R • IL1B • MSR1","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • PD-L2 • IL2 • IL10 • CSF1R • IL1B • MSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Niktimvo (axatilimab-csfr)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 11/20/2020","study_completion_date":" 11/20/2020","last_update_posted":"2024-05-17"}]